For Information
Outcomes of the 22nd ELIXIR Board meeting, 5-6 November 2024
The 22nd ELIXIR Board meeting took place from 5-6 November 2024 in Luxembourg.
We are happy to announce that the ELIXIR Board approved the Membership application submitted by the Republic of Malta and invited the country to ratify the ELIXIR Consortium Agreement (ECA). Malta will become a full Member in ELIXIR once it has completed the national ratification process.
The Board also approved Frances application for the extension of its status as a Provisional Member of ELIXIR until the end of 2026, or until it has ratified the amended ECA, whichever comes earlier. Once France has ratified the amended ECA it will cease to be a Provisional Member and become a full Member in the ELIXIR Consortium.
The Board approved the ELIXIR 2023 Annual Accounts, as well as the Work Plan and budget for the year 2025.
Regarding Commissioned Services, the funding of one CoS proposed under the People tier: ELEAD 2nd Edition: ELIXIR LEadership And Diversity mentoring programme (2025-PEOPLE-ELEAD 2.0) was additionally approved. The project is due to begin in January 2025.
In addition, four new members were appointed to the ELIXIR Scientific Advisory Board (SAB). More information will be provided once the positions have been filled.
Dr Zsuzsanna Dosztnyi (Hungary) was re-elected Vice-Chair of the ELIXIR Board for a second term for 2025 and 2026.
The Board engaged in a discussion regarding ELIXIRs involvement in the proposed 1+MG legal entity, the Genome EDIC, likely to be formed in 2025. ELIXIR Members shared their positions regarding ELIXIRs role in the established Genome EDIC and suggested a Board working group is formed to further explore ELIXIRs contribution. Board members agreed on the importance of working with health ministries in each Member country to raise awareness about ELIXIR's role and build collaboration. The possibility of an implementation partnership with the Genome EDIC was supported, while other forms of collaboration (e.g membership) are still subject to further negotiations.
For questions about the meeting or its outcomes, please contact Jo Wingender (joana.wingender@elixir-europe.org).
Key Dates and Meetings
21 November 2024 | 14:00-16:00 (CET)
5 December 2024 | 11:00-14:00 (CET)
12 December 2024 | 14:00-16:00 (CET)